

Heterocycles

Electronic Finetuning of 8-Methoxy Psoralens by Palladium-Catalyzed Coupling: Acidochromicity and Solvatochromicity

Sarah R. Geenen,^[a] Lysander Presser,^[a] Torsten Hölzel,^[b] Christian Ganter,^[b] and Thomas J. J. Müller*^[a]

Dedicated to Prof. Dr. Rudolf Knorr on the occasion of his 85th birthday

Abstract: Differently 5-substituted 8-methoxypsoralens can be synthesized by an efficient synthetic route with various cross-coupling methodologies, such as Suzuki, Sonogashira and Heck reaction. Compared to previously synthesized psoralens, thereby promising daylight absorbing compounds as potentially active agents against certain skin diseases can be readily accessed. Extensive investigations of all synthesized psoralen derivatives reveal fluorescence in the solid state as well as several distinctly emissive derivatives in solution. Donor-substituted psoralens exhibit remarkable photo-

physical properties, such as high fluorescence quantum yields and pronounced emission solvatochromicity and acidochromicity, which were scrutinized by Lippert–Mataga and Stern–Volmer plots. The results indicate that the compounds exceed the limit of visible light, a significant factor for potential applications as an active agent. In addition, (TD)DFT calculations were performed to elucidate the underlying electronic structure and to assign experimentally obtained data.

Introduction

The development of biologically active small molecules has reached increasing importance for applications in medicine,^[1] biology^[2] and biochemistry,^[3] in particular, in the fields of diagnosis and therapy^[4] of certain diseases. As a consequence exploration of novel pharmacophores and structures remains an ongoing major challenge in synthetic chemistry.^[5] In particular, photophysical properties might significantly affect the effectiveness of some active ingredients. Controlling excited state properties by diversity oriented synthetic strategies, such as multi-component processes,^[6] is becoming increasingly important.

Psoralen (Figure 1) is a privileged pharmacophore with photosensitizing character that interacts^[7] with human DNA and can be used to treat many different types of skin diseases.^[8]




Figure 1. Selected psoralen compounds.

The psoralen derivative 8-methoxypsoralen (8-MOP) can be used, for example, for the treatment of vitiligo^[9] or T-cell lymphoma^[10] and promotes the healing of psoriasis by a photochemotherapeutic approach.^[11]

The PUVA mechanism (psoralen + UVA radiation) assumes a key role in this process.^[12] Previous studies suggest that a double [2+2] cycloaddition occurs between the furan and the pyrone moieties of psoralen and the DNA.^[13] This crosslinking of the DNA structure induces apoptosis, which prevents the cell from reproducing. Recent studies also indicate that a photo-induced electron transfer competes with the cycloaddition reaction.^[7a,14]

For further advancing previous investigations and for establishing coherence between various psoralens, it is necessary to establish efficient routes to novel electronically tunable psoralens. Most of the previously known synthetic routes of psoralens start from coumarin, umbelliferon or benzofuran (Scheme 1).^[15]


Here, we report a diversity-oriented route of 8-MOP derivatives starting from pyrogallol by applying cross-coupling methodologies to 5-bromo-8-MOP for accessing donor–acceptor

[a] S. R. Geenen, L. Presser, Prof. Dr. T. J. J. Müller
Institut für Organische Chemie und Makromolekulare Chemie
Heinrich-Heine-Universität Düsseldorf
Universitätsstraße 1, 40225 Düsseldorf (Germany)
E-mail: ThomasJJ.Mueller@hhu.de

[b] Dr. T. Hölzel, Prof. Dr. C. Ganter
Institut für Anorganische Chemie und Strukturchemie I
Heinrich-Heine-Universität Düsseldorf
Universitätsstraße 1, 40225 Düsseldorf (Germany)

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/chem.201905676>.

© 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.




Scheme 1. State-of-the-art on the ring-forming psoralen synthesis.

substituted systems in which the psoralen core acts as a donor. Furthermore, photophysical properties are studied by absorption and emission spectroscopy, as well as observed solvatochromism and halochromism is reported.

Results and Discussion


Synthesis

Usually, psoralen derivatives are synthesized starting from psoralen or coumarin analogues.^[15b,16] For providing a faster and more versatile access, we established a new synthetic route. As an easily affordable starting material pyrogallol (**1**) was chosen. Methylation^[17] followed by hydroarylation^[18] with ethyl propiolate furnished 8-methoxyumbelliferon (**3**) (Scheme 2). Interestingly, until today compound **3** has only been prepared from more complex starting materials in more sophisticated syntheses.^[19] Application of the hydroarylation on 2-methoxyresorcinol (**2**) according to Costa et al.^[18a] including solvent change and stoichiometry of ethyl propiolate provided another umbelliferon derivative. The third step of the six-step synthetic route was achieved by the Williamson ether synthesis^[20] with very good yields (Scheme 2). Subsequent acetal cleavage with hydrochloric acid gave umbelliferon derivative **5**. Other acids^[21] as well as basic acetal cleavage with sodium hydroxide only led to low yields. The subsequent cyclization to 8-methoxy-psoralen (**6**) was carried out according to Nuppenon et al.^[21]


Scheme 2. Synthesis of 5-bromo-8-methoxy-psoralen (**7**).

The halogen functionality required for coupling reactions is finally introduced by bromination with hydrobromic acid in DMSO. This bromination method^[22] is easier to handle than direct bromination with elemental bromine. Furthermore, the 8-methoxy-psoralen (**6**) is efficiently and selectively brominated in 5-position.

5-Cyano- and 5-nitrosubstituted 8-methoxy psoralens were prepared by selective displacement. After failed Beller cyanation,^[23] cyanation using zinc cyanide^[24] was attempted and the cyano product **8** was obtained in 77% yield (Scheme 3). The intended product **8** has so far only been prepared based on other psoralen intermediates, for example, 5-formyl-8-methoxy-psoralen.^[25] In addition, 5-nitro-8-methoxy-psoralen (**9**) was prepared under nitration conditions according to Yue et al.^[26]

Scheme 3. Synthesis of 5-cyano-8-methoxy-psoralen (**8**) and 5-nitro-8-methoxy-psoralen (**9**). a) 4.00 mol% Zn(OAc)₂, 4.00 mol% Zn, 1.20 equivalents Zn(CN)₂, 0.20 mol% Pd₂(dba)₃, 0.48 mol% dppf, DMF/H₂O (1:0.001), 16 h, 100 °C. b) glacial acetic acid/HNO₃ (2:1), 1 h, 0 °C–RT.

Starting from compound **7**, several functionalization reactions such as Suzuki, Sonogashira and Heck coupling could be established for variation of the aryl substituent at position 5. Using Suzuki coupling, various acceptors and donors were introduced under conditions shown in Scheme 4. With Pd(PPh₃)₄ as the standard catalyst and potassium carbonate as the base,















Scheme 4. Suzuki synthesis of 5-(hetero)aryl substituted 8-methoxy-psoralens **11**.

seven different novel 5-(hetero)aryl substituted 8-methoxyypsoralens (**11a–g**) have been synthesized.

Specific deviations from standard conditions had to be implemented for coupling of the pyridine derivative (Table 1, entry 4). 4-Pyridinylboronic acid (**10d**) possesses ligand properties that can inhibit reductive elimination and reduce the amount of the active catalyst in the final step of the Suzuki

coupling cycle. This assumption is confirmed by the fact that an increase in catalyst loading led to higher yields. Moreover, in a particular case higher yields were achieved using tri-*tert*-butylphosphonium tetrafluoroborate as a ligand and Pd(dba)₂ as a catalyst with potassium hydroxide as a base (Table 1, entry 2). However, applying these conditions to the other boronic acids did not lead to increased yields. By using 4-

Table 1. Suzuki synthesis of 5-(hetero)aryl substituted 8-methoxyypsoralens **11**.

Entry	Boronic acid, R ¹ B(OH) ₂ 10	5-Substituted 8-methoxyypsoralen 11 (yield) ^[a]
1		 11 a (59%)
2		 11 b (61%; 99% ^[b])
3		 11 c (43%)
4 ^[c]		 11 d (50%)
5		 11 e (59%)
6		 11 f (31%)
7 ^[d]		 11 g (54%)

[a] Yields after chromatography on silica gel. [b] 1.50 mol % Pd(dba)₂, 3.00 equivalents KF, 3.00 mol % [(*t*Bu)₃PH][BF₄]. [c] 18.0 mol % Pd(PPh₃)₄. [d] 1.10 equivalents R¹B(OH)₂, 20.0 mol % Pd₂(dba)₃, 3.00 equivalents KF, 26.0 mol % SPhos.

carboxyphenylboronic acid (**10g**), it was necessary to switch to completely different conditions ($\text{Pd}_2(\text{dba})_3$, SPhos as a ligand, and KF as a base) to reach conversion (Table 1, entry 7).

Additionally, it was possible to corroborate the structure of 5-(hetero)aryl substituted 8-methoxypsoralens **11** by an X-ray crystal structure analysis of compound **11a** (Figure 2).^[27] The brownish block-shaped compound crystallizes with a centrosymmetric arrangement in the monoclinic space group $P2_1/c$. The cyanophenyl moiety is twisted with the psoralen core by an angle of $57.01(4)^\circ$. Furthermore, analysis of the crystal packing reveals that the psoralen cores are self-oriented in a planar fashion. Thereby two furan (3.424 Å) and two pyrone units (3.708 Å) are mutually stacked on top of each other. The plane distance between furan and pyrone (3.208 Å) is even shorter, rationalizing π -stacking of the molecules.






Figure 2. a) X-ray structure of compound **11a** (thermal ellipsoids for N, O, and C shown at 40% probability); b) Crystal packing of compound **11a** with shortest interplanar distances between furan and pyrone moieties.

Subsequently, various ethynyl and vinyl aryl substrates **12** and **14** were coupled to the 5-position of 8-methoxypsoralen under Sonogashira and Heck conditions with the same catalyst and ligand system consisting of $\text{Pd}_2(\text{dba})_3$ and cataCXium PtB to give the corresponding 5-(hetero)aryl alkynyl substituted 8-methoxypsoralens **13** and 5-(hetero)aryl vinyl substituted 8-methoxypsoralens **15** (Scheme 5 and 6). For both series four examples with electron-withdrawing groups and one example with a dimethylamino group as electron-donating substituents were synthesized (Table 2 and 3). As previously shown for the Suzuki coupling, double amounts of catalyst and ligand were used for successful transformation of pyridyl derivatives (Table 2 and 3, entries 4). All obtained psoralen derivatives **11**, **13**, and **15** were purified by precipitation or column chromatography and then recrystallized in various solvents. Structures and purity were confirmed by ^1H , ^{13}C NMR, mass spectrometry, high resolution mass spectrometry, HPLC and elemental analysis.

An X-ray crystal structure analysis of alkyne-linked compound **13e** was obtained.^[27,28] The yellow acicular crystals with the monoclinic space group $P2_1/c$ crystallize planar due to the rigid character of the ethynyl bridge (Figure 3). The centrosymmetric arrangement, supported by the short interplanar distances between the molecules (<3.4 Å), enables a close inter-



Scheme 5. Sonogashira synthesis of 5-(hetero)aryl alkynyl substituted 8-methoxypsoralens **13**.



Scheme 6. Heck synthesis of 5-(hetero)aryl vinyl substituted 8-methoxypsoralens **15**.














Figure 3. a) X-ray structure of compound **13e** (thermal ellipsoids for N, O, and C shown at 40% probability), top: top-view, bottom: side-on-view; b) Crystal packing of compound **13e** with shortest interplanar distances between furan and pyrone moieties and between pyrone and *N,N*-dimethyl aniline moieties.

action of the molecules in the crystalline solid state. These interactions cause a pronounced π -stacking, which appears to be relevant for the observed solid state luminescence (vide infra).

Table 2. Sonogashira synthesis of 5-(hetero)aryl alkynyl substituted 8-methoxypsoralens 13.			
Entry	Arylalkyne 12		5-Substituted 8-methoxypsoralen 13 (yield) ^[a]
1		12a	 13 a (21 %)
2		12b	 13 b (25 %)
3		12c	 13 c (45 %)
4 ^[b]		12d	 13 d (64 %)
5		12e	 13 e (63 %)











[a] Yields after chromatography on silica gel. [b] 1.00 mol% Pd₂(dba)₃, 4.00 mol% cataCXium PtB (2-(di-*tert*-butyl-phosphino)-1-phenyl-1*H*-pyrrole).

Photophysical properties

Most of the synthesized psoralen derivatives **8**, **9**, **11**, **13**, and **15** are novel chromophores and have not been photophysical-

ly investigated so far. A peculiar aspect is that psoralen by its furo (donor) and α -pyrone (acceptor) anellation represents a donor—acceptor chromophore per se, which acts electronically amphiphilic. This means 8-MOP can adopt a donor and ac-

Table 3. Heck synthesis of 5-(hetero)aryl vinyl substituted 8-methoxypsoralens **15**.

Entry	Vinyl (hetero)aryene 14	5-Substituted 8-methoxypsoralen 15 (yield) ^[a]
1		 15 a (39%)
2		 15 b (69%)
3		 15 c (69%)
4 ^[b]		 15 d (29%)
5		 15 e (57%)

[a] Yields after chromatography on silica gel. [b] 1.00 mol% Pd₂(dba)₃, 4.00 mol% cataCXium PtB (2-(di-*tert*-butyl-phosphino)-1-phenyl-1*H*-pyrrole).

ceptor function depending on the electronic nature of the 5-substituent. Based on a library of 5-substituted 8-methoxypsoralens systematic studies of the absorption and emission properties were conducted. The relative fluorescence quantum yield Φ_F was determined with Coumarin 30 as a standard.^[28]

All 5-acceptor-8-methoxypsoralens **8**, **9**, and **11** exhibit a shoulder as the longest wavelength absorption between 355 and 412 nm, with molar absorption coefficients, ϵ , between 2700 and 6700 Lmol⁻¹ cm⁻¹ (Table 4). The longest wavelength bands of cyano and nitro psoralens **8** and **9** are more bathochromically shifted than those of aryl-substituted psoralens **11**,

Compound	$\lambda_{\max,abs}$ [nm] ^[a] (ϵ [$M^{-1} cm^{-1}$])	$\lambda_{\max,em}$ [nm] ^[b] (Φ_F [a.u.])	Stokes shift $\Delta\bar{\nu}$ [cm^{-1}] ^[c]
8	355 (6700), 380 (3300sh)	–	–
9	394 (7400), 412 (5200sh)	–	–
11 a	310 (16400), 359 (3600sh)	–	–
11 b	309 (16100), 371 (6700sh)	–	–
11 c	313 (18300), 365 (3900sh)	–	–
11 d	307 (15200), 355 (3100sh)	–	–
11 e	327 (8000sh), 380 (5100)	557 (0.27)	8400
11 f	310 (5600), 360 (1000sh)	–	–
11 g	311 (15600), 359 (2700sh)	–	–

[a] Recorded in CH_2Cl_2 , $c(\mathbf{8})$, $c(\mathbf{9})$, $c(\mathbf{11}) = 10^{-5} M$ at $T = 293 K$. [b] Recorded in CH_2Cl_2 , $c(\mathbf{8})$, $c(\mathbf{9})$, $c(\mathbf{11}) = 10^{-7} M$ at $T = 293 K$, relative quantum yields were determined with Coumarin 30 as a standard in acetonitrile ($\Phi_F = 0.67$ ^[28]). [c] $\Delta\bar{\nu} = \frac{1}{\lambda_{\max,abs}} - \frac{1}{\lambda_{\max,em}}$

plausibly rationalized by the expected twist between the aryl moiety and the psoralen core, resulting in a weaker orbital overlap.

Only the donor-substituted psoralen **11 e** has a distinct longest wavelength band at $\lambda_{\max,abs} = 380$ nm ($\epsilon = 5100$ $Lmol^{-1} cm^{-1}$, Table 4, entry 4, Figure 4). Furthermore, only this compound fluoresces in dichloromethane with a substantial fluorescence quantum yield of 27%.




Figure 4. Normalized UV/Vis absorption (recorded in CH_2Cl_2 , $T = 293 K$, $c(\mathbf{8})$, $c(\mathbf{9})$, $c(\mathbf{11}) = 10^{-5} M$, bold lines) and emission bands (recorded in CH_2Cl_2 , $T = 293 K$, $c(\mathbf{8})$, $c(\mathbf{9})$, $c(\mathbf{11}) = 10^{-7} M$, dashed lines) of compounds **8**, **9** and **11**.

All other 8-methoxypsoralens **8**, **9**, and **11** only fluoresce in the solid state, however, only very weakly in solution (Figure 5). Strongly acceptor- (**9**, **11 b**) and donor-substituted derivatives (**11 e**) possess redshifted absorptions that correlate to HOMO–LUMO transitions as supported by TD–DFT calculations (vide infra and for further details, see Supporting Information).

Ethynyl substituted psoralens **13** differ from compounds **11** by pronounced redshifted maxima of the longest wavelength absorption bands in UV/Vis spectra (Table 5, Figure 6). Also the molar extinction coefficients are substantially higher (between 8800 and 20000 $Lmol^{-1} cm^{-1}$). Compounds **13 b**, with the strongest acceptor, and **13 e**, with the strongest donor, exhibit



Figure 5. Fluorescence of psoralen derivatives **8**, **9** and **11** in solid state (upper row) and in dichloromethane (lower row, $c(\mathbf{8})$, $c(\mathbf{9})$, $c(\mathbf{11}) = 10^{-7} M$, hand-held UV-Lamp, $\lambda_{exc} = 365$ nm).

Compound	$\lambda_{\max,abs}$ [nm] ^[a] (ϵ [$M^{-1} cm^{-1}$])	$\lambda_{\max,em}$ [nm] ^[b] (Φ_F [a.u.])	Stokes shift $\Delta\bar{\nu}$ [cm^{-1}] ^[c]
13 a	346 (24800), 374 (13100)	474 (0.07)	5600
13 b	358 (19200), 388 (18400)	565 (0.03)	8100
13 c	350 (29700), 377 (19300)	464 (0.09)	5000
13 d	341 (20000), 368 (8800)	465 (0.09)	5900
13 e	359 (22100), 403 (20000)	553 (0.28)	6700

[a] Recorded in CH_2Cl_2 , $c(\mathbf{13}) = 10^{-5} M$ at $T = 293 K$. [b] Recorded in CH_2Cl_2 , $c(\mathbf{13}) = 10^{-7} M$ at $T = 293 K$, relative quantum yields were determined with Coumarin 30 as a standard in acetonitrile ($\Phi_F = 0.67$). [c] $\Delta\bar{\nu} = \frac{1}{\lambda_{\max,abs}} - \frac{1}{\lambda_{\max,em}}$




Figure 6. Normalized UV/Vis absorption (recorded in CH_2Cl_2 , $T = 293 K$, $c(\mathbf{13}) = 10^{-5} M$, bold lines) and emission bands (recorded in CH_2Cl_2 , $T = 293 K$, $c(\mathbf{13}) = 10^{-7} M$, dashed lines) of compounds **13**.

the largest bathochromic shift probably due to a charge transfer state. Interestingly, the latter is the first psoralen derivative absorbing light in the visible.

Compared to compounds **8**, **9**, and **11** the relative fluorescence quantum yields of compounds **13** in solution increase significantly with values between 3 and 28% (Table 5, Figure 7). The nitro-substituted psoralen **13 b** fluoresces the least, which is due to its competitive deactivation of the electronic excitation energy by predissociation.^[29]



Figure 7. Fluorescence of psoralen derivatives **13** (left) and **15** (right) in solid state (upper row) and dichloromethane (lower row, $c(\mathbf{13}), c(\mathbf{15}) = 10^{-7}$ M, hand-held UV-Lamp, $\lambda_{\text{exc}} = 365$ nm).

The vinyl-substituted psoralen derivatives **15** possess most redshifted longest wavelength absorption bands in these psoralen series (Table 6, Figure 8). Additionally, the longest wavelength absorption bands of compounds **15a–d** can only be recognized as weak shoulders (Figure 8).

Despite the mostly dissociative nature of the nitro group, compound **15b** unexpectedly fluoresces with a substantial fluorescence quantum yield of 13% (Table 6, entry 2). All psoralen compounds **15** particularly fluoresce in the solid state. As

Table 6. Selected photophysical properties of 5-substituted 8-methoxy-psoralens **15**.

Compound	$\lambda_{\text{max,abs}}$ [nm] ^[a] (ϵ [$\text{M}^{-1} \text{cm}^{-1}$])	$\lambda_{\text{max,em}}$ [nm] ^[b] (Φ_f [a.u.])	Stokes shift $\Delta\tilde{\nu}$ [cm^{-1}] ^[c]
15a	329 (13400), 385 (9300sh)	477 (0.09)	5000
15b	362 (21200), 396 (20600sh)	583 (0.13)	8100
15c	342 (24400), 386 (14700sh)	498 (0.04)	5800
15d	327 (21700), 378 (7200sh)	497 (0.05)	6300
15e	358 (18100), 403 (16300)	553 (0.13)	6700

[a] Recorded in CH_2Cl_2 , $c(\mathbf{15}) = 10^{-5}$ M at $T = 293$ K. [b] Recorded in CH_2Cl_2 , $c(\mathbf{15}) = 10^{-7}$ M at $T = 293$ K, relative quantum yields were determined with Coumarin 30 as a standard in acetonitrile ($\Phi_f = 0.67^{[28]}$). [c] $\Delta\tilde{\nu} = \frac{1}{\lambda_{\text{max,abs}}} - \frac{1}{\lambda_{\text{max,em}}}$




Figure 8. Normalized UV/Vis absorption (recorded in CH_2Cl_2 , $T = 293$ K, $c = 10^{-5}$ M, bold lines) and emission bands (recorded in CH_2Cl_2 , $T = 293$ K, $c = 10^{-7}$ M, dashed lines) of compounds **15**.

in the series **11** and **13** dimethylamino-substituted psoralens reveal pronounced positive emission solvatochromicity. Most remarkably these compounds cover a spectral range from blue emission in cyclohexane to orange-red emission in acetonitrile (Figure 9). The solvatochromicity of compound **15e** was studied in more detail. Therefore, absorption and emission spectra were recorded in solvents of different polarity. The absorption solvatochromicity in the range from 392 to 413 nm turns out to be weak. In comparison, the emission solvatochromicity with a bathochromic shift of 499 to 684 nm is very strong (for details, see Supporting Information).



Figure 9. Fluorescence of compound **15e** in solvents of different polarity (from left to right: cyclohexane, toluene, chloroform, ethyl acetate, dichloromethane, dimethyl sulfoxide, *N,N*-dimethylformamide, acetonitrile; $\lambda_{\text{exc}} = 365$ nm).

This peculiar behavior originates from the change of dipole moment of the molecule upon excitation by UV light and the concomitant relaxation of surrounding solvent molecules.^[30] Quantitative calculation of this dipole moment change can be performed with the Lippert–Mataga model.^[31] Initially, the orientation polarizability Δf of different solvents is determined according to the following equation [Eq. (1)]:

$$\Delta f = \frac{\epsilon_r - 1}{2\epsilon_r + 1} - \frac{n^2 - 1}{2n^2 + 1} \quad (1)$$

ϵ_r describes the relative permittivity and n the refractive index of the respective solvent.^[30] Subsequently the orientation polarizability Δf can be plotted against the Stokes shift $\Delta\tilde{\nu}$. The regression correlates with an excellent goodness of fit ($r^2 = 0.98$, for further details, see Supporting Information).

The Stokes shift can be described using the Lippert–Mataga equation [Eq. (2)] by the change of the dipole moment from the ground to the excited state.

$$\tilde{\nu}_o - \tilde{\nu}_f = \frac{2\Delta f}{4\pi\epsilon_0 h c a^3} (\mu_E - \mu_G)^2 + \text{const} \quad (2)$$

The parameters $\tilde{\nu}_o$ and $\tilde{\nu}_f$ define the absorption and emission maxima (in cm^{-1}). ϵ_0 is the vacuum permittivity constant ($8.8542 \cdot 10^{-12} \text{ AsV}^{-1} \text{m}^{-1}$) and h is the Planck's constant ($6.6256 \cdot 10^{-34} \text{ Js}$). Furthermore, c describes the speed of light ($2.9979 \cdot 10^{10} \text{ cms}^{-1}$) and a the radius of the solvent cavity which occupies the investigated molecule. Finally, μ_E and μ_G refer to the dipole moment in the ground and excited state. The parameter a could be determined by assuming a spherical dipole

using DFT calculations in the optimized ground state. This Onsager radius a is 5.83 Å ($5.83 \cdot 10^{-10}$ m). With the determined parameters and constants, for compound **13e** a change of dipole moment $\Delta\mu$ of 13 D ($4.28 \cdot 10^{-29}$ Cm) results. For the other donor-substituted psoralens **11e** and **15e**, the change in the dipole moment $\Delta\mu$ values amount to 12 D ($3.88 \cdot 10^{-29}$ Cm) and 19 D ($6.43 \cdot 10^{-29}$ Cm), respectively. The differences in the change of dipole moment indicate the increase in charge transfer character with extension of the π -system.

Protonation of chromophores **11e**, **13e** and **15e** in dichloromethane reveals another photophysical effect. The protonation of the compounds significantly changes the absorption and emission behavior (Figure 10). Upon addition of trifluoroacetic acid the solutions' yellowish color disappears with concomitant fluorescence quenching. Upon addition of triethylamine this acidochromicity can be reversed and luminescence returns.




Figure 10. Psoralen derivatives **11e**, **13e** and **15e** in dichloromethane (left) and with dichloromethane and trifluoroacetic acid (right) at daylight (top row, $c = 10^{-5}$ M) and under the hand-held UV lamp (top bottom, $c = 10^{-5}$ M, $\lambda_{exc} = 365$ nm).

Thereby, it was also possible to determine the pK_a value of the chromophores **11e**, **13e** and **15e**. Assuming complete dissociation of trifluoroacetic acid in dichloromethane the pK_a values were determined by recording the absorption spectra at different pH values. For compound **13e** a hypsochromic shift of the absorption maximum at 403 nm to a shoulder at 371 nm was monitored (Figure 11). For **13e-H⁺** a pK_a value of 2.81 could be determined (for experimental details, see Supporting Information). Likewise the aryl derivative **11e** gives a pK_a of 3.05, whereas for the styryl derivative **15e** a pK_a of 3.28 can be determined.

In addition, monitoring the fluorescence quenching by trifluoroacetic acid the pK_a values of the chromophores **11e**, **13e** and **15e** were alternatively determined from the resulting Stern–Volmer^[32] plots revealing linear correlations of the fluorescence intensities F_0/F with the concentration of the trifluoroacetic acid solution $c(\text{TFA})$ (for details, see Supporting Information). The determined Stern–Volmer constant K_{sv} of compound **13e** is $155.93 \text{ L mol}^{-1}$, corresponding to a pK_a value of 2.15, which is in good agreement with the pK_a value determined by absorption spectroscopy. The pK_a values by Stern–Volmer plots




Figure 11. Absorption and emission spectra of **13e** in the presence of increasing amounts of trifluoroacetic acid (recorded in CH_2Cl_2 , $c(\mathbf{13e}) = 2.78 \cdot 10^{-4}$ M (absorption), $c = 1.11 \cdot 10^{-4}$ M (emission; $\lambda_{exc} = 403$ nm) $T = 293$ K).

of compounds **11e-H⁺** and **15e-H⁺** were also determined to 3.31 and 3.45, respectively, corresponding very well with the previously determined values by absorption spectroscopy. The obtained values are typical of *para*-substituted amines,^[33] therefore it can be assumed that the protonation occurs at the dimethylamino nitrogen atom, which is additionally supported by NMR spectra of the unprotonated and protonated species (for further details, see Supporting Information).

The comparison of the three *p*-dimethylamino phenyl derivatives **11e**, **13e**, and **15e**, giving the highest fluorescence quantum yields in dichloromethane within all three consanguineous series, reveals that the emission maxima lie in a very narrow margin between 553 and 557 nm. This accounts for a very similar electronic structure of the vibrationally relaxed excited state. For the alkynyl derivative **13e** the solid state spectrum was detected at 557 nm, that is, at a very similar energy. In addition the chromophores **11e**, **13e**, and **15e** were embedded in PMMA (polymethylmethacrylate) films at 1 wt% and their emission maxima appear at 500 (**11e**), 523 (**13e**), and 547 nm (**15e**), that is, hypsochromically shifted in comparison to the solution emission maxima. This slight blue shift can be rationalized by the polarity effect of the PMMA matrix (for spectra, see Supporting Information).

Calculated electronic structure

For gaining an insight in the electronic structure of these T-shaped 8-methoxy psoralen chromophores, in which the psoralen moiety and the 5-substituents adopt rectangular orientations, TD-DFT calculations were performed for the chromophores **11a**, **11e**, **13a**, **13e**, **15a** and **15e**. The geometry of the electronic ground state structures was optimized using Gaussian 09,^[34,35] with the PBE1PBE^[35] functional and the Pople 6-311G(d,p)^[36] base set. Since all photophysical measurements were carried out in dichloromethane solutions, the polarizable continuum model (PCM) with dichloromethane as a solvent was used.^[37] Geometry optimization shows that the torsional angle between the aryl moiety and the psoralen core lies between 55 and 57° for all molecules synthesized by Suzuki cou-

pling. This is in good agreement with the torsional angles extracted from crystal structure analyses. Molecules synthesized by Sonogashira coupling are essentially coplanar due to the ethynyl bridge. The Heck derivatives possess torsional angles of the styryl substituents between 33 to 34°.

Starting from the geometry optimized structures, the lowest energy electronic transitions of chromophores **11a**, **11e**, **13a**, **13e**, **15a** and **15e** were calculated on the TD-DFT level of theory with the Pople 6-21G basis set (Table 7).^[38] The comparison considers in each series the cyano-substituted (acceptor) and the dimethylamino-substituted (donor) derivatives. The calculations confirm that the experimentally assessed longest wavelength absorption bands (maxima and shoulders) can be clearly assigned to HOMO–LUMO transitions.

8-MOP as an electronic amphiphile can adopt either donor or acceptor functionality depending on the remote substituent's electronic nature. This can be clearly visualized by the molecules' FMOs, reflecting the Franck–Condon transition of the longest wavelength absorption band.

The calculated frontier molecule orbitals (FMO) indicate that the coefficient densities in HOMOs predominantly reside on

the 5-substituents. The LUMOs, however, predominantly localize coefficient density on the psoralen units (Figure 12). The dominance of the HOMO–LUMO transitions clearly rationalize the charge transfer character of these dominant low energy absorption bands, as well as the pronounced emission solvatochromicity. In addition the T-shape of two constituting subchromophores, biaryl, tolane, and stilbene, and psoralen enables the design of rectangular excited state coupled chromophores with considerable alteration of dipole moment orientation. Furthermore the tunability of absorption and emission characteristics makes these novel chromophores interesting candidates for photo-induced DNA-crosslinking.

Conclusions

A novel route from pyrogallol to 5-bromo-8-methoxypsoralen was established. Several new chromophores with functional donor and acceptor groups were synthesized by different cross-coupling methodologies, such as Suzuki, Sonogashira or Heck reactions. These psoralen series absorb at wavelengths around 400 nm and possess highly interesting emission prop-

Table 7. TD-DFT calculations (PBE1PBE/6-21G) of the UV/Vis absorption maxima of 11a < 11e < 13a < 13e < 15a and 15e using PCM with dichloromethane as solvent.				
	$\lambda_{\text{max,abs}}$ [nm] ^[a] (ϵ [$\text{M}^{-1} \text{cm}^{-1}$])	$\lambda_{\text{max,calcd}}$ [nm]	Dominant contributions	Oscillator strength
11a	359 (3600sh)	355	HOMO→LUMO (96%)	0.2066
	310 (16400)	313	HOMO→LUMO+1 (93%)	0.1376
11e	380 (5100)	400	HOMO→LUMO (99%)	0.2105
	327 (8000sh)	319	HOMO–1→LUMO (91%)	0.0147
13a	374 (13100sh)	397	HOMO→LUMO (97%)	0.8154
	346 (24800)	329	HOMO→LUMO+1 (74%)	0.3676
13e	403 (20000)	442	HOMO→LUMO (98%)	0.6549
	359 (22100)	337	HOMO–1→LUMO (66%)	0.1754
15a	385 (9300sh)	403	HOMO→LUMO (98%)	0.7491
	329 (13400)	337	HOMO→LUMO+1 (87%)	0.2324
15e	403 (16300)	445	HOMO→LUMO (99%)	0.6721
	358 (18100)	337	HOMO→LUMO+1 (50%)	0.2719




Figure 12. Selected Kohn–Sham FMOs of psoralens **11a** < **11e** < **13a** < **13e** < **15a** and **15e** (with PBE1PBE/6-311G(d,p) and PCM with dichloromethane as solvent).

erties with relative fluorescence quantum yields of up to 28%. Besides pronounced positive emission solvatochromicity reversible fluorescence quenching by acidochromicity can be assessed. Experimentally the highly polar nature of the excited state was supported by determining the change of dipole moments according to the Lippert–Mataga model. The acidochromicity and protic emission quenching was quantitatively investigated by determining pK_a values of these psoralen chromophores by absorption photometry and by Stern–Volmer plots. TD–DFT calculations using the PBE1PBE functional can successfully applied to elucidate the nature of the longest wavelength absorption bands.

With the embedded multifunctionality these novel psoralen derivatives are promising candidates for PUVA therapy at lower energies. Their bathochromic absorption does not require the use of ultraviolet light, potentially also daylight suffices. In addition, these sensitivity to polar and protic environments encourage to scout for applications in biophysical analytics as well as theranostic agents.^[39]

Experimental Section

All experimental details, such as preparations, typical procedures, and all ^1H and ^{13}C NMR spectra, absorption and emission spectra, solvatochromicity and acidochromicity studies as well as crystal structures and quantum chemical calculations are included in the Supporting Information.

Acknowledgements

We cordially thank the Deutsche Forschungsgemeinschaft (Mu 1088/14-1, Mu 1088/9-1) for the financial support. Computational support and infrastructure were provided by the “Centre for Information and Media Technology” (ZIM) at the University of Düsseldorf (Germany). We cordially thank T. Wilcke (Heinrich-Heine-Universität Düsseldorf) for taking the photographs for this paper.

Conflict of interest

The authors declare no conflict of interest.

Keywords: acidochromism · cross-coupling reactions · density functional calculations · donor–acceptor dyes · solvatochromism · UV/Vis spectroscopy

- [1] a) S. N. Chee, L. Novakovic, H. Fassih, T. Garibaldino, R. Sarkany, *Brit. J. Dermatol.* **2018**, *178*, e189–e190; b) L. Song, B. Yu, L. Yang, Z.-x. Wang, Y. Zhang, Y.-I. Yu, K. Zhou, *Basic Clin. Pharmacol. Toxicol.* **2019**, *125*, 527–535; c) K. Tsubouchi, H. Kato, E. Nishida, R. Ohguchi, Y. Shintani, A. Morita, *J. Dermatol.* **2015**, *42*, 1114–1115; d) H. Chen, J. Yang, L. Sun, H. Zhang, Y. Guo, J. Qu, W. Jiang, W. Chen, J. Ji, Y.-W. Yang, B. Wang, *Small* **2019**, *15*, 1903880.
- [2] B. Armitage, *Chem. Rev.* **1998**, *98*, 1171–1200.
- [3] A. Hashimoto, T. Takamura-Enya, Y. Oda, *Photochem. Photobiol.* **2019**, *95*, 1403–1411.
- [4] E. D. Sternberg, D. Dolphin, C. Brückner, *Tetrahedron* **1998**, *54*, 4151–4202.

- [5] L. F. Tietze, K. Schmuck, H. J. Schuster, M. Müller, I. Schuberth, *Chem. Eur. J.* **2011**, *17*, 1922–1929.
- [6] T. J. J. Müller, *Drug Discov. Today Technol.* **2018**, *29*, 19–26.
- [7] a) S. Fröbel, L. Levi, S. M. Ulamec, P. Gilch, *ChemPhysChem* **2016**, *17*, 1377–1386; b) K. Toshima, S. Takai, Y. Maeda, R. Takano, S. Matsumura, *Angew. Chem. Int. Ed.* **2000**, *39*, 3656–3658; *Angew. Chem.* **2000**, *112*, 3802–3804.
- [8] a) J. W. Tessman, S. T. Isaacs, J. E. Hearst, *Biochemistry* **1985**, *24*, 1669–1676; b) D. P. Chakraborty, S. Roy, A. K. Chakraborty, *Pigment Cell Res.* **1996**, *9*, 107–116.
- [9] J. A. Parrish, T. B. Fitzpatrick, C. Shea, M. A. Pathak, *Arch. Dermatol.* **1976**, *112*, 1531–1534.
- [10] D. Humme, A. Nast, R. Erdmann, S. Vandersee, M. Beyer, *Cancer Treat. Rev.* **2014**, *40*, 927–933.
- [11] R. S. Stern, *New Engl. J. Med.* **2007**, *357*, 682–690.
- [12] a) V. Richer, S. AlObaida, P. Kharazmi, T. K. Lee, S. Kalia, H. Lui, *Br. J. Dermatol.* **2019**, *181*, 417–418; b) V. Brazzelli, S. Grassi, S. Merante, V. Grasso, R. Ciccocioppo, G. Bossi, G. Borroni, *Photodermatol. Photoimmunol. Photomed.* **2016**, *32*, 238–246; c) N. Kitamura, S. Kohtani, R. Nakagaki, *J. Photochem. Photobiol. C* **2005**, *6*, 168–185.
- [13] R. Johnson, L. Staiano-Coico, L. Austin, I. Cardinale, R. Nabeya-Tsukifuji, J. G. Krueger, *Photochem. Photobiol.* **1996**, *63*, 566–571.
- [14] J. Diekmann, J. Gontcharov, S. Fröbel, C. Torres Ziegenbein, W. Zinth, P. Gilch, *J. Am. Chem. Soc.* **2019**, *141*, 13643–13653.
- [15] a) E. Bisagni, *J. Photochem. Photobiol. B* **1992**, *14*, 23–46; b) B.-L. Zhang, F.-D. Wang, J.-M. Yue, *Synlett* **2006**, 0567–0570.
- [16] a) E. Späth, M. Pailer, *Ber. Dtsch. Chem. Ges.* **1934**, *67*, 1212–1213; b) J. N. Rây, S. S. Silooja, V. R. Vaid, *J. Chem. Soc.* **1935**, 813–816; c) V. K. Ahluwalia, C. Prakash, S. Bala, *Monatsh. Chem.* **1980**, *111*, 877–882.
- [17] V. S. Raju, G. V. Subbaraju, M. S. Manhas, Z. Kaluza, A. K. Bose, *Tetrahedron* **1992**, *48*, 8347–8352.
- [18] a) R. A. Leao, P. de F. de Moraes, M. C. B. C. Pedro, P. R. R. Costa, *Synthesis* **2011**, 3692–3696; b) J. M. Timonen, R. M. Nieminen, O. Sareila, A. Goulas, L. J. Moilanen, M. Haukka, P. Vainiotalo, E. Moilanen, P. H. Aulaskari, *Eur. J. Med. Chem.* **2011**, *46*, 3845–3850.
- [19] a) E. Späth, H. Schmid, *Ber. Dtsch. Chem. Ges.* **1941**, *74*, 193–196; b) T. Harayama, K. Katsuno, Y. Nishita, M. Fujii, *Chem. Pharm. Bull.* **1994**, *42*, 1550–1552; c) Y. Yoshida, S.-i. Nagai, N. Oda, J. Sakakibara, *Synthesis* **1986**, 1026–1027.
- [20] S. Venkatraman, F. Velazquez, S. Gavalas, W. Wu, K. X. Chen, A. G. Nair, F. Bennett, Y. Huang, P. Pinto, Y. Jiang, *Bioorg. Med. Chem.* **2013**, *21*, 2007–2017.
- [21] J. I. Maki, P. J. Malkonen, H. E. Nupponen, United States Patent US4169840 A, **1979**.
- [22] S. Song, X. Sun, X. Li, Y. Yuan, N. Jiao, *Org. Lett.* **2015**, *17*, 2886–2889.
- [23] A. W. Franz, L. N. Popa, T. J. J. Müller, *Tetrahedron Lett.* **2008**, *49*, 3300–3303.
- [24] Ł. J. Weseliński, R. Luebke, M. Eddaoudi, *Synthesis* **2014**, *46*, 596–599.
- [25] W. S. El-Hamouly, A. F. Aboulez, *Indian J. Chem. Sect. B* **1986**, *25*, 373–376.
- [26] B.-L. Zhang, C.-Q. Fan, L. Dong, F.-D. Wang, J.-M. Yue, *Eur. J. Med. Chem.* **2010**, *45*, 5258–5264.
- [27] Deposition Numbers 1971801 (11a) and 1971800 (15e) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service www.ccdc.cam.ac.uk/structures.
- [28] G. Jones, W. R. Jackson, C. Y. Choi, W. R. Bergmark, *J. Phys. Chem.* **1985**, *89*, 294–300.
- [29] C. Kosmidis, K. W. D. Ledingham, A. Clark, A. Marshall, R. Jennings, J. Sander, R. P. Singhal, *Int. J. Mass Spectrom. Ion Processes* **1994**, *135*, 229–242.
- [30] J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, 3rd ed., Springer, Heidelberg, **2006**.
- [31] a) E. Lippert, *Ber. Bunsenges. Phys. Chem.* **1957**, *61*, 962–975; b) N. Mataga, Y. Kaifu, M. Koizumi, *Bull. Chem. Soc. Jpn.* **1956**, *29*, 465–470.
- [32] O. Stern, M. Volmer, *Phys. Z.* **1919**, *20*, 183–188.
- [33] P. H. Grantham, E. K. Weisburger, J. H. Weisburger, *J. Org. Chem.* **1961**, *26*, 1008–1017.
- [34] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Na-

- katsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, Gaussian, Inc., Wallingford CT, **2009**.
- [35] a) J. P. Perdew, K. Burke, M. Ernzerhof, *Phys. Rev. Lett.* **1996**, *77*, 3865; b) D. D. Yu, J. M. Huss, H. Li, B. M. Forman, *Bioorg. Med. Chem.* **2017**, *25*, 1585–1599; c) C. Adamo, V. Barone, *J. Chem. Phys.* **1999**, *110*, 6158–6170.
- [36] a) A. D. McLean, G. S. Chandler, *J. Chem. Phys.* **1980**, *72*, 5639–5648; b) R. Krishnan, J. S. Binkley, R. Seeger, J. A. Pople, *J. Chem. Phys.* **1980**, *72*, 650–65.
- [37] G. Scalmani, M. J. Frisch, *J. Chem. Phys.* **2010**, *132*, 114110.
- [38] a) J. S. Binkley, J. A. Pople, W. J. Hehre, *J. Am. Chem. Soc.* **1980**, *102*, 939–947; b) M. S. Gordon, J. S. Binkley, J. A. Pople, W. J. Pietro, W. J. Hehre, *J. Am. Chem. Soc.* **1982**, *104*, 2797–2803.
- [39] a) S. S. Kelkar, T. M. Reineke, *Bioconjugate Chem.* **2011**, *22*, 1879–1903; b) S. Frangos, J. R. Buscombe, *Eur. J. Nucl. Med. Mol. Imaging* **2019**, *46*, 519.

Manuscript received: December 17, 2019

Accepted manuscript online: February 12, 2020

Version of record online: May 29, 2020